Jazz Pharmaceuticals plc
General ticker "JAZZ" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.5B (TTM average)
Jazz Pharmaceuticals plc follows the US Stock Market performance with the rate: 51.8%.
Estimated limits based on current volatility of 1.9%: low 184.02$, high 190.59$
Factors to consider:
- Total employees count: 2800 as of 2024
- US accounted for 90.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Commercialization of zepzelca, Clinical trial delays, Regulatory and compliance, Market competition, Acquisition/divestiture risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [143.66$, 221.72$]
- 2026-12-31 to 2027-12-31 estimated range: [136.05$, 212.85$]
Financial Metrics affecting the JAZZ estimates:
- Negative: with PPE of 20.6 at the end of fiscal year the price was high
- Positive: Operating cash flow per share per price, % of 13.16 > 12.96
- Positive: -4.75 < Operating profit margin, % of 5.26
- Positive: 19.40 < Shareholder equity ratio, % of 37.04 <= 42.68
- Positive: -3.43 < Return on assets ratio (scaled to [-100,100]) of -2.96
- Negative: Industry earnings per price (median), % of -14.30 <= 0
Short-term JAZZ quotes
Long-term JAZZ plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $3,834.20MM | $4,068.95MM | $4,267.59MM |
| Operating Expenses | $3,255.62MM | $3,352.32MM | $4,043.16MM |
| Operating Income | $578.58MM | $716.63MM | $224.42MM |
| Non-Operating Income | $-280.65MM | $-246.28MM | $-853.01MM |
| Interest Expense | $289.44MM | $238.10MM | $195.05MM |
| R&D Expense | $849.66MM | $884.00MM | $782.74MM |
| Income(Loss) | $297.93MM | $470.35MM | $-628.59MM |
| Taxes | $-119.91MM | $-91.43MM | $-272.44MM |
| Other Income(Loss) | $-3.01MM | $-1.66MM | $0.00MM |
| Profit(Loss)* | $414.83MM | $560.12MM | $-356.15MM |
| Stockholders Equity | $3,737.00MM | $4,093.76MM | $4,318.58MM |
| Inventory | $597.04MM | $480.44MM | $416.96MM |
| Assets | $11,393.36MM | $12,012.26MM | $11,659.34MM |
| Operating Cash Flow | $1,092.01MM | $1,395.91MM | $1,355.77MM |
| Capital expenditure | $23.96MM | $48.07MM | $58.75MM |
| Investing Cash Flow | $-163.06MM | $-508.19MM | $-1,509.91MM |
| Financing Cash Flow | $-305.25MM | $20.52MM | $-873.38MM |
| Earnings Per Share** | $6.55 | $9.06 | $-5.84 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.